DPPE in Combination With Epirubicin and Cyclophosphamide in the Treatment of Breast Cancer
The purpose of this trial is to study DPPE combined with epirubicin and cyclophosphamide in patients with metastatic and/or recurrent breast cancer who may have received previous hormone treatment but have not had exposure to anthracycline treatment. Stratification allocation will be within the following subgroups:

1. Prior cytotoxic treatment;
2. Estrogen receptor status;
3. ECOG performance status;
4. Number of cycles of chemotherapy.
Breast Cancer|Metastases
DRUG: YMB 1002
Overall survival
Response rate|Progression-free survival|Toxicity|Neurocognitive function
Endpoints of the trial are as follows:

primary: overall survival; secondary: response rate, progression free survival, toxicity, neurocognitive function.